IceCure Medical (NASDAQ: ICCM) has announced positive topline results from the ICESECRET clinical study of its ProSense Cryoablation System for the treatment of small renal masses in kidney cancer patients.
Detailed data from the study will be presented by principal investigator Prof. Halahmi Sarel at the European Conference on Interventional Oncology in Basel, Switzerland from April 26 to 30, 2026.
In a statement, Eyal Shamir, CEO of IceCure, commented, “We believe the positive top-line results from this study further reinforce cryoablation with ProSense as an effective and durable treatment option for patients with small renal masses. We believe these findings may help drive broader commercial adoption of ProSense in countries where it is already approved to treat kidney tumors, as physicians and healthcare systems continue to seek minimally invasive alternatives with strong long-term outcomes.”
